355 related articles for article (PubMed ID: 17296442)
1. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation.
Boucher W; Kempuraj D; Cao J; Papaliodis D; Theoharides TC
J Urol; 2007 Mar; 177(3):1186-90. PubMed ID: 17296442
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effect of IPD-1151T (suplatast tosilate) on mast cell induction from normal mouse spleen cells].
Kouno S; Adachi M; Asano K; Okamoto K; Takahashi T
Arerugi; 1992 Oct; 41(10):1488-91. PubMed ID: 1336362
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid.
Kirimoto T; Nakano K; Irimura K; Hayashi Y; Matsuura N; Kiniwa M; Oka T; Yoshimura N
BJU Int; 2007 Oct; 100(4):935-9. PubMed ID: 17714534
[TBL] [Abstract][Full Text] [Related]
4. Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants.
Cao J; Boucher W; Kempuraj D; Donelan JM; Theoharides TC
J Urol; 2006 Sep; 176(3):1208-13. PubMed ID: 16890727
[TBL] [Abstract][Full Text] [Related]
5. Intravesical nanocrystalline silver decreases experimental bladder inflammation.
Boucher W; Stern JM; Kotsinyan V; Kempuraj D; Papaliodis D; Cohen MS; Theoharides TC
J Urol; 2008 Apr; 179(4):1598-602. PubMed ID: 18295255
[TBL] [Abstract][Full Text] [Related]
6. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T.
Ueda T; Tamaki M; Ogawa O; Yamauchi T; Yoshimura N
J Urol; 2000 Dec; 164(6):1917-20. PubMed ID: 11061880
[TBL] [Abstract][Full Text] [Related]
7. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress.
Boucher WS; Letourneau R; Huang M; Kempuraj D; Green M; Sant GR; Theoharides TC
J Urol; 2002 Jan; 167(1):380-4. PubMed ID: 11743360
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect of anti-allergic agent suplatast tosilate (IPD-1151T) on methacholine- and allergen-induced bronchoconstriction in sensitized mice. asakazu@med.showa-u.dc.jp.
Asano K; Mizutani T; Shimane T; Hisano M; Hisamitsu T; Suzaki H
Mediators Inflamm; 2000; 9(2):77-84. PubMed ID: 10958380
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytes.
Konno S; Adachi M; Asano K; Gonogami Y; Ikeda K; Okamoto K; Takahashi T
Eur J Pharmacol; 1994 Jun; 259(1):15-20. PubMed ID: 7957588
[TBL] [Abstract][Full Text] [Related]
10. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
[TBL] [Abstract][Full Text] [Related]
11. [Effect of suplatast tosilate (IPD-1151T) on types I-IV allergic reactions].
Matsuura N; Mori H; Nagai H; Koda A
Nihon Yakurigaku Zasshi; 1992 Dec; 100(6):495-501. PubMed ID: 1282894
[TBL] [Abstract][Full Text] [Related]
12. Effect of IPD-1151T (Suplatast Tosilate) on airway hyperresponsiveness in mice.
Konno S; Asano K; Gonokami Y; Kurokawa M; Kawazu K; Adachi M
Arerugi; 1995 May; 44(5):556-61. PubMed ID: 7619009
[TBL] [Abstract][Full Text] [Related]
13. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (1). Regulation of murine IgE response.
Yanagihara Y; Kiniwa M; Ikizawa K; Yamaya H; Shida T; Matsuura N; Koda A
Jpn J Pharmacol; 1993 Jan; 61(1):23-30. PubMed ID: 8382322
[TBL] [Abstract][Full Text] [Related]
14. Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis.
Chiang G; Patra P; Letourneau R; Jeudy S; Boucher W; Green M; Sant GR; Theoharides TC
J Urol; 2000 Dec; 164(6):2119-25. PubMed ID: 11061939
[TBL] [Abstract][Full Text] [Related]
15. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response.
Yanagihara Y; Kiniwa M; Ikizawa K; Shida T; Matsuura N; Koda A
Jpn J Pharmacol; 1993 Jan; 61(1):31-9. PubMed ID: 8382323
[TBL] [Abstract][Full Text] [Related]
16. [A case of eosinophilic cystitis that was treated with oral suplatast tosilate (IPD-1151T)].
Watanabe M; Yamaguchi K; Yamanishi T; Kamai T; Yoshida K
Hinyokika Kiyo; 2009 Nov; 55(11):715-9. PubMed ID: 19946192
[TBL] [Abstract][Full Text] [Related]
17. IPD-1151T: a prototype drug for IgE antibody synthesis modulation.
Koda A; Yanagihara Y; Matsuura N
Agents Actions Suppl; 1991; 34():369-78. PubMed ID: 1665310
[TBL] [Abstract][Full Text] [Related]
18. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
[TBL] [Abstract][Full Text] [Related]
19. IPD-1151T (suplatast tosilate) inhibits interleukin (IL)-13 release but not IL-4 release from basophils.
Shichijo M; Shimizu Y; Hiramatsu K; Togawa M; Inagaki N; Takagi K; Nagai H
Jpn J Pharmacol; 1999 Apr; 79(4):501-4. PubMed ID: 10361893
[TBL] [Abstract][Full Text] [Related]
20. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo.
Kurokawa M; Kawazu K; Asano K; Fumio K; Mita A; Adachi M
Mediators Inflamm; 2001 Dec; 10(6):333-7. PubMed ID: 11817674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
